Scalability study on [La]LaCl production with a focus on potential clinical applications.

Background: In recent years, targeted alpha therapy has gained importance in the clinics, and in particular, the alpha-emitter Ac plays a fundamental role in this clinical development. Nevertheless, depending on the chelating system no real diagnostic alternative has been established which shares similar chemical properties with this alpha-emitting radionuclide. In fact, the race to launch a diagnostic radionuclide to form a matched pair with Ac is still open, and La features attractive radiation properties to claim this place.

Production of the PET radionuclide Cu via the Ni(p,2n)Cu nuclear reaction.

Background: There are only a handful of true theranostic matched pairs, and in particular the theranostic radiocopper trio Cu, Cu and Cu, for diagnosis and therapy respectively, is a very attractive candidate. In fact, the alternative of two imaging radionuclides with different half-lives is a clear advantage over other theranostic pairs, since it offers a better matching for the tracer biological and radionuclide physical half-lives. Due to the high availability of Cu, its translation into the clinic is being successfully carried out, giving the example of the FDA approved radiopharmaceutical Detectnet (copper Cu 64 dotatate injection).

Cyclotron-Based Production of Cu for Radionuclide Theranostics via the Zn(p,α)Cu Reaction.

Theranostic matched pairs of radionuclides have aroused interest during the last couple of years, and in that sense, copper is one element that has a lot to offer, and although Cu and Cu are slowly being established as diagnostic radionuclides for PET, the availability of the therapeutic counterpart Cu plays a key role for further radiopharmaceutical development in the future. Until now, the Cu shortage has not been solved; however, different production routes are being explored. This project aims at the production of no-carrier-added Cu with high radionuclidic purity with a medical 30MeV compact cyclotron via the Zn(p,α)Cu reaction.

Efficient Production of the PET Radionuclide La for Theranostic Purposes in Targeted Alpha Therapy Using the Ba(p,2n)La Reaction.

Targeted Alpha Therapy is a research field of highest interest in specialized radionuclide therapy. Over the last decades, several alpha-emitting radionuclides have entered and left research topics towards their clinical translation. Especially, 225Ac provides all necessary physical and chemical properties for a successful clinical application, which has already been shown by [225Ac]Ac-PSMA-617.

Recent Insights in Barium-131 as a Diagnostic Match for Radium-223: Cyclotron Production, Separation, Radiolabeling, and Imaging.

Barium-131 is a single photon emission computed tomography (SPECT)-compatible radionuclide for nuclear medicine and a promising diagnostic match for radium-223/-224. Herein, we report on the sufficient production route Cs(,)Ba by using 27.5 MeV proton beams.